Session 7: Richter Transformation

Co-Chair(s)

• 

  Gianluca Gaidano, MD, PhD

  Professor of Hematology
  University of Eastern Piedmont, Maggiore Charity Hospital
  Novara, Italy
• 

  Silvia Deaglio, MD, PhD

  Professor of Medical Genetics
  University of Turin
  Turin, Italy

Presentations:

• 12:05 - 12:20 CEST

  Disease Profiling to Identify Potential Therapeutic Targets in Richter Transformation
  

  Speaker: Erin M. Parry, MD, PhD – Dana-Farber Cancer Institute, Harvard Medical School
• 12:20 - 12:35 CEST

  Current and Future Management of Richter Transformation
  

  Speaker: Othman Al-Sawaf, MD – Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital
• 12:35 - 12:45 CEST

  Panel Discussion With Interactivity and Audience Q&A
• 12:45 - 12:55 CEST

  MGA Loss drives cristae remodeling and redox adaptation via MICOS and PRDX2 in Richters transformation
  

  Primary Author / Presenter: Prajish S. Iyer, PhD – Department of Systems Biology, Beckman Research Institute, City of Hope
• 12:55 - 13:05 CEST

  Epcoritamab Monotherapy in Patients with First-Line Richter’s Transformation: 2-Year Follow-Up Results From the Phase 1b/2 EPCORE CLL-1 Clinical Trial
  

  Primary Author / Presenter: Arnon P. Kater, MD, PhD – Department of Hematology, Amsterdam UMC, Cancer Center Amsterdam, University of Amsterdam, and HOVON